• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 3:30:52 PM ET
    $CNCE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNCE alert in real time by email
    SC 13G/A 1 d74809dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Concert Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    206022 105

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 206022 105

     

      1    

      NAMES OF REPORTING PERSONS

     

      Perceptive Advisors LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      2,150,641

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      2,150,641

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,150,641

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      7.0%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IA


    CUSIP No. 206022 105

     

      1    

      NAMES OF REPORTING PERSONS

     

      Joseph Edelman

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      2,150,641

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      2,150,641

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,150,641

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      7.0%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN


    CUSIP No. 206022 105

     

      1    

      NAMES OF REPORTING PERSONS

     

      Perceptive Life Sciences Master Fund Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      2,150,641

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      2,150,641

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,150,641

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      7.0%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO


    Item 1(a).

    Name of Issuer:

    Concert Pharmaceuticals, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    65 Hayden Avenue, Suite 3000N, Lexington, MA 02421

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Perceptive Advisors LLC (“Perceptive Advisors”)

    Joseph Edelman (“Mr. Edelman”)

    Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    51 Astor Place, 10th Floor

    New York, NY 10003

     

    Item 2(c).

    Citizenship:

    Perceptive Advisors is a Delaware limited liability company

    Mr. Edelman is a United States citizen

    The Master Fund is a Cayman Islands corporation

     

    Item 2(d).

    Title of Class of Securities:

    Common stock, $0.001 par value per share (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    206022 105

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 30,649,249 outstanding shares of Common Stock, as reported in the Issuer’s Form 10-Q filed on November 5, 2020.

    The Master Fund directly holds 2,150,641 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own the securities directly held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the securities directly held by the Master Fund.


    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 16, 2021

     

    PERCEPTIVE ADVISORS LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title: Managing Member

     

    /s/ Joseph Edelman
    JOSEPH EDELMAN

     

    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By:   Perceptive Advisors LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title: Managing Member
    Get the next $CNCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNCE

    DatePrice TargetRatingAnalyst
    10/5/2021$13.00 → $9.00Buy
    Mizuho
    More analyst ratings

    $CNCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Stuart Nancy sold $50,380 worth of shares (6,048 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 262,596 units (withholding obligation)

      4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

      2/16/23 8:51:22 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Munsie Jeffrey A sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 88,049 units to cover withholding tax

      4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

      2/16/23 8:49:56 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Cassella James V sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 173,061 units to satisfy withholding obligation

      4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

      2/16/23 8:48:59 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Concert Pharmaceuticals Inc.

      15-12G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

      3/16/23 9:00:55 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Concert Pharmaceuticals Inc.

      EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

      3/14/23 12:15:21 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Concert Pharmaceuticals Inc.

      EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

      3/14/23 12:15:15 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Leadership Updates

    Live Leadership Updates

    See more
    • KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors

      CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has been appointed to its Board of Directors effective March 18, 2021. Ms. Stuart is Chief Operating Officer at Concert Pharmaceuticals Inc. (NASDAQ: CNCE) and is a leader in strategic planning, business operations and business development in the biopharmaceutical and biotechnology industries. “We are pleased to welcome Nancy to our Board of Directors. Her experience at a broad range of companies from both a

      3/19/21 7:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CNCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CNCE
    Financials

    Live finance-specific insights

    See more
    • SEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)

      SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

      2/14/23 4:45:50 PM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)

      SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

      2/14/23 2:35:53 PM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Concert Pharmaceuticals Inc.

      SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

      2/13/23 9:25:22 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

      Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibitor, is being developed for the treatment of adult patients with moderate to severe alopecia areata. In light of the FDA approval of a different JAK inhibitor as the first treatment for alopecia areata, the FDA previously notified Concert that it was reviewing the Breakthrough Therapy designation previously granted for deuruxolitinib. At the FDA's request, Concert submitted additional clinical data an

      2/15/23 7:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

      Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sales M

      1/19/23 9:39:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

      Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sale

      1/19/23 8:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

      Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sales M

      1/19/23 9:39:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

      Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sale

      1/19/23 8:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results

      Company Plans to Submit NDA in First Half of 2023 for Deuruxolitinib in Adults with Moderate to Severe Alopecia Areata Deuruxolitinib (CTP-543) Phase 3 Data Presented at the EADV Congress Late Breaking News Session Additional Deuruxolitinib Phase 3 Results to be Presented at the World Congress for Hair Research Conference Call Scheduled Today at 8:30 a.m. ET; Registration Required to Join Live Call Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the third quarter of 2022. "With the THRIVE-AA clinical program completed and positive Phase 3 results in hand for deuruxolitinib in alopecia areata, we are well on our way to meeting our goal of submitting the

      11/7/22 7:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho reiterated coverage on Concert Pharmaceuticals with a new price target

      Mizuho reiterated coverage of Concert Pharmaceuticals with a rating of Buy and set a new price target of $9.00 from $13.00 previously

      10/5/21 7:29:28 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist reiterated coverage on Concert Pharmaceuticals with a new price target

      Truist reiterated coverage of Concert Pharmaceuticals with a rating of and set a new price target of $22.00 from $30.00 previously

      2/2/21 11:37:54 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist Securities reiterated coverage on Concert Pharmaceuticals with a new price target

      Truist Securities reiterated coverage of Concert Pharmaceuticals with a rating of Buy and set a new price target of $22.00 from $30.00 previously

      2/2/21 11:13:03 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care